title: Antibody-engineered nanoparticles selectively inhibit mesenchymal cells isolated from patients with chronic lung allograft dysfunction.
abstract: OBJECTIVE
  Chronic lung allograft dysfunction represents the main cause of death after lung transplantation, and so far there is no effective therapy. Mesenchymal cells (MCs) are primarily responsible for fibrous obliteration of small airways typical of chronic lung allograft dysfunction. Here, we engineered gold nanoparticles containing a drug in the hydrophobic section to inhibit MCs, and exposing on the outer hydrophilic surface a monoclonal antibody targeting a MC-specific marker (half-chain gold nanoparticles with everolimus).
  
  
  METHODS
  Half-chain gold nanoparticles with everolimus have been synthesized and incubated with MCs to evaluate the effect on proliferation and apoptosis.
  
  
  CONCLUSIONS
  Drug-loaded gold nanoparticles coated with the specific antibody were able to inhibit proliferation and induce apoptosis without stimulating an inflammatory response, as assessed by in vitro experiments.
  
  
  CONCLUSIONS
  These findings demonstrate the effectiveness of our nanoparticles in inhibiting MCs and open new perspectives for a local treatment of chronic lung allograft dysfunction.
authors.affiliation: Clinica di Malattie dell'Apparato Respiratorio, IRCCS Fondazione Policlinico S Matteo, viale Golgi 19, 27100 Pavia, Italy. f.meloni@smatteo.pv.it.
authors.forename: Emanuela
authors.initials: E
authors.lastname: Cova
authors.forename: Miriam
authors.initials: M
authors.lastname: Colombo
authors.forename: Simona
authors.initials: S
authors.lastname: Inghilleri
authors.forename: Monica
authors.initials: M
authors.lastname: Morosini
authors.forename: Simona
authors.initials: S
authors.lastname: Miserere
authors.forename: Jesus
authors.initials: J
authors.lastname: Peñaranda-Avila
authors.forename: Benedetta
authors.initials: B
authors.lastname: Santini
authors.forename: Davide
authors.initials: D
authors.lastname: Piloni
authors.forename: Sara
authors.initials: S
authors.lastname: Magni
authors.forename: Furio
authors.initials: F
authors.lastname: Gramatica
authors.forename: Davide
authors.initials: D
authors.lastname: Prosperi
authors.forename: Federica
authors.initials: F
authors.lastname: Meloni
mesh_terms: D000328:Adult; D000368:Aged; D064591:Allografts / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000737:chemistry / Q000276:immunology; D017209:Apoptosis / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects*; D000068338:Everolimus; D005260:Female; D006046:Gold / Q000008:administration & dosage / Q000737:chemistry; D006801:Humans; D018960:Hyaluronan Receptors / Q000276:immunology; D016040:Lung Transplantation / Q000009:adverse effects*; D008297:Male; D059630:Mesenchymal Stem Cells / Q000187:drug effects* / Q000276:immunology; D053768:Metal Nanoparticles / Q000008:administration & dosage / Q000737:chemistry; D008875:Middle Aged; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000737:chemistry
chemical_list: D000911:Antibodies, Monoclonal; D018960:Hyaluronan Receptors; D006046:Gold; D000068338:Everolimus; D020123:Sirolimus
keywords: antifibrotic agent; bronchiolitis obliterans syndrome; chronic lung allograft dysfunction; mesenchymal cell; targeted drug-loaded nanoparticle